LABCORP HOLDINGS INC.
LHAPI behind this page
LH Q3 2025 request
Playground key active
/api/financials?ticker=LH&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 3,563.5 | 3,282 | +8.6% |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services · Operating Segments | 799.1 | 737.7 | +8.3% |
| Diagnostics · Operating Segments | 2,769.6 | 2,553.5 | +8.5% |
Show Geography breakouts |
|||
| US | 2,968.5 | 2,738.4 | +8.4% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | 5.2 | 9.2 | -43.5% |
| Cost of Revenue | 2,538.4 | 2,377.6 | +6.8% |
| Gross Profit | 1,025.1 | 904.4 | +13.3% |
| Selling, General & Administrative | 552.4 | 568.6 | -2.8% |
| Amortization Of Intangible Assets | 69.5 | 63.7 | +9.1% |
| Asset Impairment Charges | 0.7 | — | — |
| Net Restructuring And Other Special Charges | 5.9 | 18 | -67.2% |
| Operating Income | 396.6 | 254.1 | +56.1% |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services · Operating Segments | 132.2 | 120.9 | +9.3% |
| Corporate | -109.9 | -172.5 | +36.3% |
| Diagnostics · Operating Segments | 450.4 | 387.4 | +16.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 582.6 | 508.3 | +14.6% |
| Interest Expense | -56 | -50.4 | -11.1% |
| Investment Income Net | 3.5 | 3.1 | +12.9% |
| Income Loss From Equity Method Investments | -5.2 | -0.5 | -940.0% |
| Other Non-Operating Income (Expense) | -1.9 | 4.3 | -144.2% |
| Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest | 337 | 210.6 | +60.0% |
| Income Tax Expense (Benefit) | 75.5 | 41 | +84.1% |
| Net Income | 261.5 | 169.6 | +54.2% |
| Net Income Loss Attributable To Noncontrolling Interest | -0.4 | -0.3 | -33.3% |
| Net Income | 261.1 | 169.3 | +54.2% |
Show Equity Components breakouts |
|||
| Retained Earnings | 261.1 | 169.3 | +54.2% |
| EPS (Basic) | 3.14 | 2.02 | +55.4% |
| EPS (Diluted) | 3.12 | 2 | +56.0% |
| Comprehensive Income | 253.7 | 248.1 | +2.3% |
| Wtd Avg Shares (Basic) | 83.1 | 84 | -1.1% |
| Wtd Avg Shares (Diluted) | 83.7 | 84.4 | -0.8% |
| Labor And Related Expense (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services | 313.8 | 293.1 | +7.1% |
| Diagnostics | 1,200.6 | 1,146.3 | +4.7% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 598.1 | — | — |
| Accounts Receivable | 2,109.1 | — | — |
| Unbilled Contracts Receivable | 156.1 | — | — |
| Inventory | 521.5 | 483.1 | +7.9% |
| Prepaid Expense Current | 694 | 684.7 | +1.4% |
| Total Current Assets | 4,078.8 | 4,909.9 | -16.9% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,112.8 | 3,050 | +2.1% |
| Goodwill | 6,682.3 | — | — |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services | 1,350.3 | — | — |
| Diagnostics | 5,332 | — | — |
| Other Non-Current Assets | 648.1 | 612.6 | +5.8% |
| Total Assets | 18,261.6 | 18,612.5 | -1.9% |
| Intangible Assets | 3,007 | — | — |
Show Schedule Of Other Intangible Assets By Major Class [Axis] breakouts |
|||
| Customer Relationships | 2,682.8 | — | — |
| Noncompete Agreements | 93.6 | — | — |
| Other Intangible Assets | 12.8 | — | — |
| Patents, Licenses And Technology [Member] | 217.8 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 3,571.4 | — | — |
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | 168.2 | 16.9 | +895.3% |
| Current Liabilities | |||
| Accounts Payable | 668.5 | 660.9 | +1.1% |
| Accrued Liabilities | 878 | 757.5 | +15.9% |
| Deferred Revenue | 391.6 | 403.1 | -2.9% |
| Operating Lease Liability Current | 186.7 | 184.3 | +1.3% |
| Finance Lease Liability Current | 4.5 | 6.3 | -28.6% |
| Short Term Debt And Along Term Debt Current Maturities | 499.9 | — | — |
| Total Current Liabilities | 2,629.2 | 3,412 | -22.9% |
| Non-Current Liabilities | |||
| Long-Term Debt | 5,082.5 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Senior notes due 2029 and 2034 | 600 | — | — |
| Operating Lease Liabilities | 692 | 701.3 | -1.3% |
| Finance Lease Liability Noncurrent | 64.3 | 75.2 | -14.5% |
| Other Non-Current Liabilities | 639.1 | 528.2 | +21.0% |
| Total Liabilities | 9,548.6 | 10,427.1 | -8.4% |
| Other Liabilities | |||
| Deferred Income Taxes And Other Tax Liabilities | 441.5 | 358.3 | +23.2% |
| Noncontrolling Interest Mezzanine Equity | 16.1 | 15.2 | +5.9% |
| Stockholders' Equity | |||
| Common Stock | 7.5 | 7.6 | -1.3% |
| Additional Paid In Capital Common Stock | 33 | — | — |
| Retained Earnings | -8,698.4 | -8,275.8 | -5.1% |
| Accumulated Other Comprehensive Income | -42 | -113.2 | +62.9% |
| Total Stockholders' Equity | 8,696.9 | 8,170.2 | +6.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -42 | -113.2 | +62.9% |
| Additional Paid In Capital | 33 | — | — |
| Common Stock | 7.5 | 7.6 | -1.3% |
| Retained Earnings | 8,698.4 | 8,275.8 | +5.1% |
| Total Liabilities & Equity | 18,261.6 | 18,612.5 | -1.9% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 508.1 | 472.9 | +7.4% |
| Stock-Based Compensation | 96.1 | 89.4 | +7.5% |
| Depreciation And Amortization Of Leased Assets | 149.1 | 136.7 | +9.1% |
| Goodwill And Intangible Asset Impairment | 0.7 | 2.5 | -72.0% |
| Deferred Income Taxes | 76.4 | -58.6 | +230.4% |
| Other Operating Activities Cash Flow Statement | 51.7 | 46 | +12.4% |
| Change in Accounts Receivable | -130.4 | -143.2 | +8.9% |
| Increase Decrease In Contract With Customer Asset | 3.9 | 22.8 | -82.9% |
| Change in Inventory | -17.9 | 2 | -995.0% |
| Change in Prepaid & Other Assets | 15.8 | -39.8 | +139.7% |
| Change in Accounts Payable | -204.4 | -138.2 | -47.9% |
| Increase Decrease In Deferred Revenue | -12.6 | -27.9 | +54.8% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -223 | -159.5 | -39.8% |
| Net Cash from Operations | 1,026.3 | 808.6 | +26.9% |
| Investing Activities | |||
| Capital Expenditures | -310.6 | -377.8 | +17.8% |
| Proceeds From Sale Of Property Plant And Equipment | 3.5 | 0.6 | +483.3% |
| Proceeds From Sale Of Other Investments | 6.9 | — | — |
| Payments To Acquire Investments | -179.9 | -42.3 | -325.3% |
| Payments To Acquire Businesses Net Of Cash Acquired | -324 | -751.2 | +56.9% |
Show Business Acquisition breakouts |
|||
| Empire City Laboratories, Inc. | -250 | — | — |
| Net Cash from Investing | -804.1 | -1,157.2 | +30.5% |
| Financing Activities | |||
| Repayments Of Senior Debt | -1,000 | -600 | -66.7% |
| Proceeds From Long Term Lines Of Credit | 64.8 | 2,463.7 | -97.4% |
| Repayments Of Lines Of Credit | -64.8 | -2,463.7 | +97.4% |
| Proceeds From Accounts Receivable Securitization | 225 | 300 | -25.0% |
| Tax Withholding for Share Compensation | -30.6 | -38.7 | +20.9% |
| Net Proceeds From Issuance Of Stock To Employees | 54.3 | 53 | +2.5% |
| Payments Of Dividends | -181.4 | -183 | +0.9% |
| Share Repurchases | -225 | -175 | -28.6% |
| Proceeds From Payments For Other Financing Activities | -8.9 | -29.7 | +70.0% |
| Net Cash from Financing | -1,166.6 | 1,326.6 | -187.9% |
| Supplemental | |||
| Income Taxes Paid | 159.7 | 194.5 | -17.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 23.8 | 2.5 | +852.0% |
| Net Change in Cash | -920.6 | 980.5 | -193.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 598.1 | 1,517.3 | -60.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.